Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1126/scitranslmed.aah3438 http://scihub22266oqcxt.onion/10.1126/scitranslmed.aah3438 C5448557!5448557!28148840     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Transl+Med 2017 ; 9 (375): ä Nephropedia Template TP {{tp|p=28148840|t=2017. Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis |pdf=|usr=}}{{28148840}} gab.com Text Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis JO: Sci Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=28148840 #FOAvip In 2013, chikungunya virus (CHIKV) transmission was documented in the Western Hemisphere, and the virus has since spread throughout the Americas with more than 1.8 million people infected in more than 40 countries. CHIKV targets the joints, resulting in symmetric polyarthritis that clinically mimics rheumatoid arthritis and can endure for months to years. At present, no approved treatment is effective in preventing or controlling CHIKV infection or disease. We treated mice with eight different disease-modifying antirheumatic drugs and identified CLTA4-Ig (abatacept) and tofacitinib as candidate therapies based on their ability to decrease acute joint swelling. CTLA4-Ig reduced T cell accumulation in the joints of infected animals without affecting viral infection. Whereas monotherapy with CTLA4-Ig or a neutralizing anti-CHIKV human monoclonal antibody provided partial clinical improvement, therapy with both abolished swelling and markedly reduced levels of chemokines, proinflammatory cytokines, and infiltrating leukocytes. Thus, combination CTLA4-Ig and antiviral antibody therapy controls acute CHIKV infection and arthritis and may be a candidate for testing in humans. Twit Text FOAVip Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis ????Sci Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=28148840 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28148840 #FOAvip English Wikipedia <ref>{{Cite pmid|28148840}}</ref> Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis #MMPMID28148840 Miner JJ; Cook LE; Hong JP; Smith AM; Richner JM; Shimak RM; Young AR; Monte K; Poddar S; Crowe JE; Lenschow DJ; Diamond MS Sci Transl Med 2017[Feb]; 9 (375): ä PMID28148840show ga In 2013, chikungunya virus (CHIKV) transmission was documented in the Western Hemisphere, and the virus has since spread throughout the Americas with more than 1.8 million people infected in more than 40 countries. CHIKV targets the joints, resulting in symmetric polyarthritis that clinically mimics rheumatoid arthritis and can endure for months to years. At present, no approved treatment is effective in preventing or controlling CHIKV infection or disease. We treated mice with eight different disease-modifying antirheumatic drugs and identified CLTA4-Ig (abatacept) and tofacitinib as candidate therapies based on their ability to decrease acute joint swelling. CTLA4-Ig reduced T cell accumulation in the joints of infected animals without affecting viral infection. Whereas monotherapy with CTLA4-Ig or a neutralizing anti-CHIKV human monoclonal antibody provided partial clinical improvement, therapy with both abolished swelling and markedly reduced levels of chemokines, proinflammatory cytokines, and infiltrating leukocytes. Thus, combination CTLA4-Ig and antiviral antibody therapy controls acute CHIKV infection and arthritis and may be a candidate for testing in humans. äTherapy with CTLA4-Ig and an antiviral monoclonal antibody controls ch(epmc).pdf DeepDyve Pubget Overpricing